Repositioning Candidate Details
| Candidate ID: | R0630 |
| Source ID: | DB04863 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Lefradafiban |
| Synonyms: | Lefradafiban |
| Molecular Formula: | C23H25N3O6 |
| SMILES: | [H][C@@]1(COC2=CC=C(C=C2)C2=CC=C(C=C2)C(=N)NC(=O)OC)C[C@@H](CC(=O)OC)C(=O)N1 |
| Structure: |
|
| DrugBank Description: | Lefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina. |
| CAS Number: | 149503-79-7 |
| Molecular Weight: | 439.4611 |
| DrugBank Indication: | For the treatment of unstable angina. |
| DrugBank Pharmacology: | Lefradafiban, an orally active prodrug of fradafiban, is a novel glycoprotein (IIb/IIIa) inhibitor for the treatment of unstable angina. Development was discontinued in 2000 due to lack of efficacy. |
| DrugBank MoA: | GPIIb/IIIa inhibitors, such as lefradafiban, block the final common pathway of platelet aggregation. |
| Targets: | Integrin alpha-IIb; Integrin beta-3 |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|